- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...
|
- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Defining optimal therapeutic sequencing strategies in prostate cancer (PC) is challenging and may be assisted by artificial intelligence (AI)-based tools for an analysis of the medical literature. To demonstrate that INSIDE PC can help clinicians query the literature on therapeutic sequencing in PC and to develop previously unestablished practices for evaluating the outputs of AI-based support pla...
|
- Details
- Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Yu-Wei Chen discusses his research focusing on androgen receptor (AR) and neuroendocrine signatures in prostate cancer using the Caris database. This study classifies prostate tumors into four molecular subgroups, revealing significant insights into their distinct behaviors and treatment responses. Dr. Chen's findings challenge the conventional histological classifications by demonstrating variati...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Rashid Sayyid and Zach Klaassen review the 2024 NCCN Guidelines for managing very low-risk prostate cancer. Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised o...
|
- Details
- Deepak Kilari discusses a Phase II trial exploring the combination of enzalutamide with five alpha-reductase inhibitors (ARIs) for castrate-sensitive prostate cancer. Driven by observations from geriatric oncology, the study seeks alternatives to androgen deprivation therapy (ADT) for older, frail men who struggle with its side effects. The trial examines whether enzalutamide combined with dutaste...
|